Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Aptar Pharma will showcase an industry first with its PureHale device – a new portable drug delivery device designed for upper respiratory care - at CPhI Worldwide this year in Madrid.

Aptar Pharma to showcase an industry first

In addition to PureHale, Aptar Pharma will also reveal:

  • A range of new connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes
  • A portfolio of gamma-sterilized drug delivery components to reduce bioburden
  • Aptar Pharma’s Support Services initiative, a portfolio of stage-specific development packages to help customers in their journey from molecule to market.
  • “Through a wide range of consulting and services, Aptar Pharma innovates around delivery routes, effective drug delivery, testing and regulatory requirements with partners ranging from small-scale R&D firms to the largest international pharmaceutical companies. We look forward to launching our Support Services initiative at CPhI, and working with our customers to meet their development needs, said Guillaume Brouet, Vice President Analytical, Regulatory and Scientific Affairs at Aptar Pharma.”

    Along with showcasing its range of innovative drug delivery devices that address nasal, pulmonary, eye care, injectables and dermal drug delivery routes at Aptar Pharma’s exhibit stand, the company will also be sharing various new solutions in prescription and over-the-counter treatments.

    Furthermore, Aptar Pharma executives will be delivering three Pharma Insight Briefings outlining the latest trends, technology and product innovations:

    “Debunking the leachable myths of gamma sterilization: A migration study of steam vs gamma”

    Julie D. Suman, President of Next Breath, a division of Aptar Pharma, Tuesday 9 October, 11:50-12:20.

    Julie Suman will present a migration study commissioned by Aptar Pharma to assess the impact of both steam sterilization and gamma sterilization on leachable profiles.

    “Portable care for your respiratory tract: Exploring new technology platforms”

    Guenter Nadler, Director Business Development, Aptar Pharma, Tuesday 9 October, 12:30-13:00

    Guenter Nadler will discuss new trends in treating upper respiratory tract issues naturally, including new respiratory technology platforms that will meet new market needs.

    “Building a connected devices eco-system for digital medicines”

    Sai Shankar, Director Business Development, Aptar Pharma Wednesday 10 October, 13:50-14:20.

    Sai Shankar will highlight the need for a digital medicine eco-system to ensure connected devices are fully optimised through patient-centric design, secure data collection and management, and cross-platform interoperability.

    Read More

    Related news

    BIA Separations expands with new upstream processing facility

    BIA Separations expands with new upstream processing facility

    20 Sep 2018

    Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

    Read more 
    Sanofi to refocus two global business units

    Sanofi to refocus two global business units

    19 Sep 2018

    The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

    Read more 
    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    18 Sep 2018

    China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

    Read more 
    Recipharm connects to European Hub for serialisation compliance

    Recipharm connects to European Hub for serialisation compliance

    18 Sep 2018

    Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

    Read more 
    Bosch to unveil new laboratory device for continuous manufacturing

    Bosch to unveil new laboratory device for continuous manufacturing

    18 Sep 2018

    The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

    Read more 
    Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

    Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

    17 Sep 2018

    Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

    Read more 
    Cambrex expands manufacturing footprint with acquisition

    Cambrex expands manufacturing footprint with acquisition

    16 Sep 2018

    Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

    Read more 
    NMPA approves fruquintinib capsules for metastatic colorectal cancer

    NMPA approves fruquintinib capsules for metastatic colorectal cancer

    13 Sep 2018

    Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

    Read more 
    Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

    Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

    11 Sep 2018

    The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

    Read more 
    New SGS biopharmaceutical testing capabilities in Illinois

    New SGS biopharmaceutical testing capabilities in Illinois

    11 Sep 2018

    The new services will focus on quality control analysis and stability testing of biopharmaceuticals.

    Read more